How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,320 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Full Text available with Trip Pro

Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Glaucoma and dry eye disorders (DEDs) are frequent comorbidities. The antioxidant and anti-inflammatory properties of essential polyunsaturated fatty acids have been extensively studied in relation to eye diseases.Our objective was to determine the effects of oral supplementation (...) upon antioxidant/essential polyunsaturated fatty acid supplementation. Chronic instillation of antihypertensive eye drops must be considered for integrating protocols to glaucoma standards of care.

2013 Clinical interventions in aging Controlled trial quality: uncertain

122. Efficacy of Mydriatic Drops in Premature Infants

: Drug used in the examination of premature infants. to investigate side effects of eye drops used Other Name: Tropicamide and mydfline used Outcome Measures Go to Primary Outcome Measures : The mean pupillary diameter [ Time Frame: an average of 1 year ] will be measured with a ruler after 60 minutes instillation of mydriatic Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) Summary: Because of the neonatologists reported that some infants had suffered from vomiting, bradycardia, hypotonia, and aspiration risk about 30-60 minutes after the fundus examination in the intensive care unit. The investigators observed the pupil dilation effects and side effects of tipple instillation of phenylephrine 2.5% plus tropicamide 0.5% ophthalmic drop combination which the investigators routinely used in ROP examination. Condition or disease Intervention/treatment Retinopathy

2018 Clinical Trials

123. Prophylactic Treatment: Lessdropsâ„¢ vs Standard Drops Regimen

: No Criteria Inclusion Criteria: Subject is undergoing bilateral cataract extraction or refractive lens exchange with intraocular lens implantation. Willing and able to provide written informed consent for participation in the study. Willing and able to comply with scheduled visits and other study procedures. Willing and able to administer eye drops and record the times the drops were instilled. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6-15 days between (...) , LLC Collaborators: Science in Vision Imprimis Pharmaceuticals, Inc. Information provided by (Responsible Party): Carolina Eyecare Physicians, LLC Study Details Study Description Go to Brief Summary: To compare the use of a compounded eye drop containing an antibiotic, a non-steroidal and steroidal anti-inflammatory to standard of care that is the use of 3 different topical medications to prevent inflammation and infection after routine cataract surgery. Condition or disease Intervention/treatment

2018 Clinical Trials

124. Ocular Safety and Pharmacokinetics Study of FK506 Suspension Eye Drops After Corneal Transplantation Full Text available with Trip Pro

Ocular Safety and Pharmacokinetics Study of FK506 Suspension Eye Drops After Corneal Transplantation The aim of this study was to investigate the sensitization, pharmacokinetics, and absorption of FK506 after corneal transplantation.New Zealand albino rabbits were divided into normal and corneal transplantation groups. Each group was divided into 5 subgroups--saline, blank matrix, high-dose, medium-dose, and low-dose, respectively. There were 10 rabbits in each subgroup. One drop (25 μL (...) and tissue distribution determination as the former 5 rabbits in each subgroup (the second batch).Fluorescein staining and local ocular reaction provided evidence that there were no significant differences between control and FK506-instilled eyes in the rabbit model at any of the tested doses. Histologic examination revealed no ocular abnormality in the rabbits instilled with any doses of FK506 eyedrop. The peak serum concentration (C(max)) of systemic absorption ranged from 4.31±0.79 ng/mL to 14.89±6.85

2012 Journal of Ocular Pharmacology and Therapeutics

125. Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects

by (Responsible Party): Gerhard Garhofer, Medical University of Vienna Study Details Study Description Go to Brief Summary: Dry eye syndrome (DES) is a common ocular disease, especially in the elderly population. Despite many treatment approaches, instillation of topical lubricants remains the mainstay of therapy. However, most of the topical lubricants available are not very well characterized and data about efficacy is sparse. The aim of the present project is to investigate the effect of topically (...) administered Olixia pure® eye drops on tear film thickness in healthy subjects. Tear film thickness will be determined using ultra high-resolution optical coherence tomography (OCT). Measurements will be performed before instillation of the eye drops and every 10 minutes after instillation for one hour. One eye will receive Olixia pure® eye drops, the fellow eye will receive physiologic saline solution as placebo control. The study eye will be chosen randomly. Condition or disease Intervention/treatment

2013 Clinical Trials

126. Effect of nepafenac eye drops on intraocular pressure - a randomized prospective study. (Abstract)

was randomized to the treatment group, with the other eye acting as a control. Nepafenac (0.1%) eye drops were instilled 3 times a day in the eye that received treatment. Intraocular pressure (IOP) with Goldmann applanation tonometer (GAT) was measured at baseline and at 4 and 8 weeks. Proportion of eyes with an IOP elevation of >4 mm Hg was the main outcome measure.The mean age of the participants was 45.7 ± 4.4 years. Participants included 192 female and 135 male patients. The mean IOP at baseline (...) Effect of nepafenac eye drops on intraocular pressure - a randomized prospective study. To report the effect of nepafenac (0.1%) eye drops on intraocular pressure in eyes with cataract.Prospective randomized clinical trial.Three hundred and twenty-seven patients with bilateral cataracts in an institutional setting were included. All patients had a baseline intraocular pressure (IOP) ≤ 21 mm Hg without a history of intraocular surgery in the past 3 months. One eye of each individual

2013 American Journal of Ophthalmology Controlled trial quality: uncertain

127. Clinical evaluation of an oil-based lubricant eyedrop in dry eye patients with lipid deficiency. (Abstract)

) for 15 days during a run-in phase, followed by randomization. Patients then instilled HPG/PG/PL or saline QID through day 35 and as needed through day 90. Change in tear film break-up time (TFBUT), change in total ocular surface staining (TOSS) score, and Impact of Dry Eye on Everyday Life (IDEEL) were evaluated on day 35.Increase in TFBUT from baseline to day 35 was assessed during the interim and final analyses. Mean ± SE difference between the HPG/PG/PL (n = 110) and saline groups (n = 100 (...) Clinical evaluation of an oil-based lubricant eyedrop in dry eye patients with lipid deficiency. To evaluate and compare the efficacy of a lipid-based lubricant eyedrop formulation (hydroxypropyl guar/propylene glycol/phospholipid [HPG/PG/PL]) with preservative-free saline for the treatment of dry eye.This was a prospective, multicenter, randomized, single-masked, parallel-group phase 4 clinical study. Patients ≥18 years diagnosed with dry eye received 1 drop of saline 4 times daily (QID

2017 European journal of ophthalmology Controlled trial quality: uncertain

128. A standardized extract of Rhynchosia volubilis Lour. exerts a protective effect on benzalkonium chloride-induced mouse dry eye model. Full Text available with Trip Pro

ethanol extract of R. volubilis (EERV) can protect the cornea in a benzalkonium chloride (BAC)-induced mouse dry eye model.Experimental dry eye was induced by the instillation of 0.2% BAC on mouse cornea. A standardized ethanol extract of R. volubilis (EERV) was orally administered following BAC treatment. The positive control group was treated with commercial eye drops. Fluorescein staining, tear break-up time (BUT), and hematoxylin and eosin staining were evaluated on the ocular surface. Squamous (...) A standardized extract of Rhynchosia volubilis Lour. exerts a protective effect on benzalkonium chloride-induced mouse dry eye model. In contrast to other leguminous plants generally used as food, Rhynchosia volubilis Loureiro, a small soybean with a black seed coat, has been used as a traditional oriental remedy for various human diseases in Eastern Asia. In this study, we demonstrated the protective effect of R. volubilis against dry eye disease.We aimed to investigate whether a standardized

2017 Journal of Ethnopharmacology

129. Epigallocatechin Gallate-Loaded Gelatin-g-Poly(N-Isopropylacrylamide) as a New Ophthalmic Pharmaceutical Formulation for Topical Use in the Treatment of Dry Eye Syndrome Full Text available with Trip Pro

time point within 3 days of release. In a rabbit dry eye model, corneal epithelial defects was ameliorated by treatment with single-dose administration of EGCG-containing GN. Furthermore, drug molecules released from carrier materials could prevent further tear evaporation and loss of mucin-secreting goblet cells in diseased animals. Our findings suggest that GN carrier is responsible for enhanced pharmacological efficacy of topically instilled EGCG, thereby demonstrating the benefits of using (...) biodegradable in situ gelling delivery system to overcome the drawbacks of limited dry eye relief associated with eye drop dosage form.

2017 Scientific reports

130. Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study Full Text available with Trip Pro

images acquired by anterior segment spectral-domain optical coherence tomography were analyzed using National Institutes of Health's image-analysis software (ImageJ 1.44p). Tear meniscus area and tear meniscus height were measured at baseline, 5 minutes, 10 minutes, and 30 minutes after instillation of a drop of diquafosol in one eye and normal saline in the other eye. Changes in ocular surface disease index score, tear film break-up time, corneal staining score by Oxford schema, and meibomian (...) expressibility were also evaluated at baseline, and after 1 week and 1 month of a diquafosol daily regimen.Sixty eyes from 30 subjects (mean age, 29.3 years; 8 men and 22 women) were included. In eyes receiving diquafosol, tear volume was increased at 5 and 10 minutes compared with baseline. It was also higher than saline instilled eyes at 5, 10, and 30 minutes. Changes in tear volume with respect to baseline were not statistically different after the use of diquafosol for 1 month. Ocular surface disease

2017 Korean journal of ophthalmology : KJO Controlled trial quality: uncertain

131. Dry Eye Disease Study With Brimonidine

keratitis or ocular neuropathic pain Any history of eyelid surgery or intraocular/ocular surgery within the past 3 months Punctal occlusion within 3 months prior to Screening visit or during study Corneal epithelial defect larger than 1 mm2 in either eye Have active drug/alcohol dependence or abuse history Are neonates, pregnant/lactating women, children, institutionalized individuals, or others who may be considered vulnerable populations Received corticosteroid-containing eye drops within the past 7 (...) days or systemic corticosteroids/immunosuppressives within the past 3 months Received cyclosporine ophthalmic emulsion 0.05% (Restasis®) or lifitegrast ophthalmic solution 5% (Xiidra™) within 30 days prior to Screening visit In the opinion of Investigator or Study Coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance

2017 Clinical Trials

132. Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED)

) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards Other: Fingerprick autologuos blood (FAB) Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day. Other Name: FAB No Intervention: Control group Arm B - Conventional treatment only (...) " containing the substances of tears. Blood, and several blood derived products, including autologous serum, have been studied as tear substitute candidates. This study proposes to test the use of finger prick autologous blood (FAB) technique in which whole blood is applied to the eye from a cleaned finger. Condition or disease Intervention/treatment Phase Dry Eye Syndromes Other: Fingerprick autologuos blood (FAB) Not Applicable Detailed Description: Autologous serum (AS) eye drops have been found

2017 Clinical Trials

133. Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry Eye

administered four times a day for 12 weeks (90 days). Device: XLHA+CoQ10 XLHA+CoQ10 for four times a day for 12 weeks. Other Name: VisuXL® Active Comparator: Hyaluronic acid (HA) Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days). Device: Hyaluronic acid (HA) Hyaluronic acid (HA) for four times a day for 12 weeks. Outcome Measures Go to Primary Outcome Measures : Ocular Surface Disease Index (OSDI) questionnaire. [ Time Frame: Up to 90 days. ] The OSDI is assessed on a scale (...) of 0 to 100, with higher scores representing greater disability. OSDI is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function. OSDI demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. Corneal and conjunctival staining. [ Time Frame: Up to 90 days. ] Corneal and conjunctival staining of the ocular surface after instillation of vital dyes

2017 Clinical Trials

134. Intense Pulsed Light Study for Dry Eye Disease

medications which makes light therapy contraindicated (the use of doxycycline is allowed); Tattoos in the treatment area; Patients who have had intense pulsed light therapy, Lipiflow or Meibothermoflo within the past six months; Contact lens wear more than one time/week or history of refractive surgery; Glaucoma drop use Ophthalmic steroid use within the past 30 days; Punctal plugs if instilled within 30 days of the start of the study; Obvious asymmetry between the two eyes deemed significant (...) will be compared to those eyes that received gland expression only. Secondary Outcome Measures : Potential change in scores of the Ocular Surface Disease Index Questionnaire [ Time Frame: 7 Months ] Patients will complete the Ocular Surface Disease Index Questionnaire at each visit. The scores from the 7 month phone call will then be compared to scores obtained at the baseline visit. The questionnaire is assessed on a scale of 0 to 100 with higher scores representing greater dry eye disease severity

2017 Clinical Trials

135. Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye

] Tear Film Break Up Time after instillation of fluorescein dye Visual Function Assessment [ Time Frame: 28 days ] Reading Test Secondary Outcome Measures : Drop Comfort Assessment [ Time Frame: Day 1 ] The comfort of the eye drop will be performed to assess changes from baseline Visual Acuity [ Time Frame: 28 Days ] Visual Acuity will be measured using the EDTRS chart to assess changes from baseline Slit-Lamp Biomicroscopy [ Time Frame: 28 Days ] Slit lamp biomicroscopy exams will be performed (...) information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Be at least 18 years of age Provide written informed consent Have a reported history of dry eye Have a history of use of eye drops for dry eye symptoms Ocular discomfort Conjunctival redness Tear film break up time Corneal and Conjunctival Staining Exclusion Criteria: Have any clinically significant slit lamp findings at entry visit

2017 Clinical Trials

136. Safety and Efficacy of TOP1630 for Dry Eye Syndrome

: Be at least 18 years of age; Provide written informed consent; Have a reported history of dry eye; Have a history of use of eye drops for dry eye symptoms; Additionally for Part 2 Symptoms of dry eye syndrome including: Ocular discomfort Conjunctival redness Tear film break up time Schirmer test score Signs of dry eye syndrome including: Conjunctival staining score Exclusion Criteria: Have any clinically significant slit lamp findings at entry visit ; Be diagnosed with an ongoing ocular infection; Have (...) is designed to assess the safety, tolerability and efficacy of TOP1630 ophthalmic solution in subjects with Dry Eye Syndrome. Eligible subjects will be randomized double masked to either TOP1630 or placebo. Part 1 (time frame 12 days) comprises assessment of safety, tolerability and ocular comfort. Part 2 (time frame 35 days) comprises assessment of safety, tolerability and efficacy Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 69

2017 Clinical Trials

137. Optive Brand For Day And Night Dry Eye Management

: Optive® Fusion + Optive® Gel Drop Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. Outcome Measures Go to Primary Outcome Measures : Ocular Surface Disease Index (OSDI) questionnaire total score [ Time Frame: 30 Days ] Total OSDI score from Visit 1 to Visit 3 Measured lissamine green bulbar conjunctival staining (mm2) [ Time Frame: 30 (...) and conjunctiva [ Time Frame: 30 days ] Lissamine green dye is instilled into the eye. Damaged cells become stained by the dye and an assessment can be made of the state of the health of the patient's lid margin and conjunctiva. Tear Film Kinetics video recording [ Time Frame: 30 days ] A video recording is taken of a patients' eye to determine at what point the tear film disperses. Tear quality and break up time can give an indication of dry eye severity Clinical grading of ocular surface staining. [ Time

2017 Clinical Trials

138. Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 3% DE-089 ophthalmic solution Drug: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period Outcome Measures Go to Primary (...) provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 20 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: At least 6-month dry eye history Exclusion Criteria: Diagnosed with Stevens-Johnson Syndrome or ocular pemphigoid Diagnosed with keratoconjunctival chemical burns or thermal burn Eye disease other than dry eye disease which needs treatment Allergic conjunctivitis

2017 Clinical Trials

139. An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation

, will be identified at the time of a regularly scheduled exam. If the patient can get a drop onto the eye and also not touch their lids or ocular surface with the eye drop bottle, the subject will be thanked but not enrolled. All other patients who agree to participate will be enrolled. Upon completion of videotaped instillation of an eye drop, each enrolled patient will be shown a video demonstrating an instillation technique and will be given an instructional handout highlighting a proper drop instillation (...) technique. If necessary, an instillation technique will be demonstrated to them by an investigator or trained personnel. A patient will be identified as properly instilling a drop if they satisfy the following criteia: They are able to instill one (and only one) drop to the ocular surface or lower fornix without allowing the bottle touch the adnexa, eyelid, eye lashes or eye. All patients routinely return between 3 and 6 months. At this regularly scheduled visit,the investigator or trained personnel

2012 Clinical Trials

140. Evaluation of Sodium Hyaluronate Lubricating Drops Used before Insertion of Contact Lenses on Symptomatology, Severity, and Intensity of Ocular Dryness. Full Text available with Trip Pro

Evaluation of Sodium Hyaluronate Lubricating Drops Used before Insertion of Contact Lenses on Symptomatology, Severity, and Intensity of Ocular Dryness. Purpose. This study aimed to evaluate outcomes from the use of a sodium hyaluronate (SH)-based comfort drop, instilled before the insertion of contact lenses, in a population of symptomatic contact lens wearers. Methods. This was a cross-over, open-label, multi-sites study. Subjects were fitted with silicone hydrogel lenses and followed for two (...) months. Before insertion of the lenses, SH drops was instilled in the lens for half of the group. The other half did the same on the second month. Objectives and subjective outcomes were measured and compared before from baseline with the ones collected after usage of SH drops.

2014 ISRN ophthalmology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>